Grifols (GRFS) Retained Earnings (2009 - 2025)
Grifols (GRFS) posted Retained Earnings of $4.9 billion for Q4 2025, up 487.48% quarter-over-quarter from $829.2 million in Q4 2024, and up 487.48% year-on-year from $829.2 million in Q4 2024.
Grifols (GRFS) Retained Earnings (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Retained Earnings for 16 consecutive years, with $4.9 billion the latest figure, recorded in Q4 2025.
- Retained Earnings for Q4 2025 came in at $4.9 billion, up 487.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.9 billion (up 487.48% YoY), and the FY2025 annual result was $4.9 billion, up 487.48% from the prior year.
- Retained Earnings was $4.9 billion for Q4 2025 at Grifols, up from $829.2 million in the prior quarter.
- Over five years, Retained Earnings peaked at $4.9 billion in Q4 2025 and troughed at $215.9 million in Q4 2021.
- Average Retained Earnings over 5 years is $2.9 billion, with a median of $4.1 billion recorded in 2022.
- Year-over-year, Retained Earnings soared 1815.37% in 2022 and sank 80.93% in 2024.
- Over 5 years, Retained Earnings stood at $215.9 million in 2021, then jumped by 1815.37% to $4.1 billion in 2022, then grew by 5.14% to $4.3 billion in 2023, then tumbled by 80.93% to $829.2 million in 2024, then soared by 487.48% to $4.9 billion in 2025.
- Per Business Quant data, the three most recent Retained Earnings figures were $4.9 billion in Q4 2025, $829.2 million in Q4 2024, and $4.3 billion in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 29.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -14.83 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -17.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.67 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 4.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.87 Bn |
| Dec 31, 2024 | 829.23 Mn |
| Dec 31, 2023 | 4.35 Bn |
| Dec 31, 2022 | 4.14 Bn |
| Dec 31, 2021 | 215.90 Mn |
| Dec 31, 2020 | 4.50 Bn |
| Sep 30, 2020 | 4.71 Bn |
| Mar 31, 2020 | 4.44 Bn |
| Dec 31, 2019 | 3.33 Bn |
| Sep 30, 2019 | 3.10 Bn |
| Dec 31, 2018 | -28.12 Mn |
| Sep 30, 2018 | 2.85 Bn |
| Jun 30, 2018 | 2.93 Bn |
| Mar 31, 2018 | 3.73 Bn |
| Dec 31, 2017 | 2.39 Bn |
| Jun 30, 2017 | 2.23 Bn |
| Dec 31, 2016 | 1.83 Bn |
| Sep 30, 2016 | 1.89 Bn |
| Jun 30, 2016 | 1.92 Bn |
| Dec 31, 2015 | 1.50 Bn |